mechanisms behind the loss of bcma in multiple myeloma & options for patients
Published 9 months ago • 124 plays • Length 1:48Download video MP4
Download video MP3
Similar videos
-
1:21
sequencing of bcma-directed therapies for multiple myeloma
-
0:58
novel car-t constructs emerging in multiple myeloma for patients who experience loss of bcma
-
1:10
the importance of bcma, fcrh5 and gprc5d in multiple myeloma
-
3:32
myeloma: bcma loss as an escape mechanism
-
1:59
investigating the mechanisms of initial & acquired resistance to bcma car-t therapy in myeloma
-
5:55
zimmer biomet: polaris deroduction animation
-
15:58
3mensio ct pre-case planning: valve-in-valve tavr in mitroflow
-
5:01
how magnetos can help you achieve a more predictable fusion | medical animation | moa animation
-
1:39
understanding mechanisms of resistance in myeloma
-
2:02
alnuctamab, a bcma x cd3 tce, in the treatment of multiple myeloma
-
1:29
sequencing bcma-targeted therapies in myeloma
-
1:45
targetting bcma in myeloma
-
2:50
phase i study of abbv383, a novel bcmaxcd3 bispecific antibody, in r/r multiple myeloma
-
4:27
antibody-based targeting of bcma in multiple myeloma
-
6:07
magnetismm-3: elranatamab in r/r multiple myeloma naive to bcma-directed therapy
-
2:19
sequencing bcma-targeted agents in multiple myeloma
-
4:03
novel technologies in multiple myeloma and how these are changing the field
-
1:24
bispecifics & cars: bcma, gprc5d & fcrh5 sequencing
-
1:31
integrating bcma-directed bispecifics and car-t into the myeloma treatment landscape
-
1:53
phe885, a t-charge manufactured bcma-directed car-t therapy in r/r myeloma
-
3:31
phe885, a novel bcma-directed car-t therapy for patients with r/r multiple myeloma
-
1:53
the detection and management of mnts following bcma-directed car-t therapy